The Filing Desk

Ionis Pharmaceuticals vs Madrigal Pharmaceuticals

Ionis Pharmaceuticals IONS · Madrigal Pharmaceuticals MDGL · Pharmaceuticals

Madrigal Pharmaceuticals reported revenue of $958 million in fiscal 2025, about the same as Ionis Pharmaceuticals' $944 million in fiscal 2025. Ionis Pharmaceuticals' revenue grew 33.8% in its latest year, and Madrigal Pharmaceuticals' grew 432.1%. Ionis Pharmaceuticals had an operating margin of -40.5%, against -31.3% at Madrigal Pharmaceuticals. Free cash flow was −$320 million at Ionis Pharmaceuticals and −$190 million at Madrigal Pharmaceuticals.

Side by side

Ionis PharmaceuticalsMadrigal Pharmaceuticals
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$944M$958M
Revenue growth33.8%432.1%
Revenue growth a year, last 5 years5.3%—
Gross margin98.3%—
Operating margin−40.5%−31.3%
Net margin−40.4%−30.1%
Free cash flow−$320M−$190M
Free cash flow margin−33.9%−19.8%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count7.0%5.5%
Last close$27.22$396.74
P/E at the last close——
Insider trades, last 12 monthsbought $1.1 million, sold $117.5 millionsold $69.0 million
Piotroski F-score3 of 93 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Ionis PharmaceuticalsMadrigal Pharmaceuticals
Operating margin
Percent of revenue
Ionis PharmaceuticalsMadrigal Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Ionis PharmaceuticalsMadrigal Pharmaceuticals

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Ionis Pharmaceuticals and Madrigal Pharmaceuticals pages.